Sterling Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Sterling Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,139	Closed	-$252K	–	3218
2025 Q4	$252K	Buy	1,139 +68	+6%	+$11K	﹤0.01%	1249
2025 Q3	$103K	Buy	1,071 +617	+136%	+$39.4K	﹤0.01%	1519
2025 Q2	$22.1K	Buy	+454	New	+$10.9K	﹤0.01%	1758

Sterling Capital Management's CDTX Position: Q1 2026 in Review

Sterling Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 1,139 shares — an estimated $252K sold.

Sterling Capital Management first reported a position in CDTX in Q2 2025 and held it in 3 quarters. The position peaked at $252K in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Sterling Capital Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Sterling Capital Management sold 1,139 Cidara Therapeutics shares in Q1 2026, an estimated $252K.
Sterling Capital Management first reported a position in Cidara Therapeutics in Q2 2025 and held it in 3 quarters.
Sterling Capital Management's Cidara Therapeutics position peaked at $252K in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.